Gene Therapy for Heart Disease Wins Fast-Track Status – P&T Community

Gene Therapy for Heart Disease Wins Fast-Track Status
P&T Community
The FDA has granted a fast-track designation for a phase 3 study of Generx (Ad5FGF-4, Angionetics Inc.) cardiovascular angiogenic gene therapy as a one-time treatment for improving exercise tolerance in patients with angina that is refractory to ...

and more »

More here:

Gene Therapy for Heart Disease Wins Fast-Track Status - P&T Community

Related Posts

Comments are closed.